Biosimilars have become a subject of great interest in the past few years. The European
Union and the United States are seeing an increasing number of biosimilar applications and …

Background and Aims. Regulatory pathways compare biosimilars with originator molecules
only and not with other biosimilars. With the development of multiple infliximab biosimilars …

The present document is a position statement of the Mexican College of Rheumatology on
the use of biosimilars in rheumatic diseases. This position considers that biosimilars should …

Developing new biologics has led to regulations and norms aimed at guaranteeing their
safety, quality and effectiveness, in terms of marketing, prescription, use, interchangeability …

Objective: The treatment of rheumatoid arthritis (RA) is based on the inhibition of TNF. Here
we evaluated whether drugs that might inhibit TNF, such as pentoxifylline (PTX), rupatadine …

Conclusion In Europe, biosimilars are increasingly regularly prescribed drugs in paediatric
IBD. Due to their lower cost, treatment expenses have gone down considerably (up to 30 …

Clinical trials impose validation of safety and efficacy, and biosimilars have contributed large
share to the pipeline of clinical trials. These biosimilars are the therapeutic alternatives to the …

Background: Biologics have provided enhanced clinical advantages, but at expense of
enormous expenditures. The exorbitant expense of biologics was somewhat mitigated by …

El presente documento refleja el posicionamiento del Colegio Mexicano de Reumatología y
de expertos sobre el uso de medicamentos biocomparables (conocidos como biosimilares …

Objetivo: Avaliar custo-minimização da troca entre as versões referência e biossimilar
(BSM) do infliximab (IFX) em operadora de saúde com mais de 500.000 vidas. Metodologia …